Allergan (AGN) says Darpin data does not support Phase 3 trials.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500, Nasdaq futures rise on tech boost
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Oil rises on Iran war stalemate; near-term potential for further gains seen limited
- L3Harris CEO steps down amid conduct review, shares drop
Lazard Capital Upgrades Allergen (AGN) to Buy
May 2, 2013 7:11 AM EDTLazard Capital upgraded Allergen (NYSE: AGN) from Hold to Buy.
For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.
Shares of Allergen closed at $98.67 yesterday, with a 52 week range of $81.28-$116.45.... More
Morgan Stanley Downgrades Allergen (AGN) to Equalweight
May 1, 2013 2:31 PM EDTMorgan Stanley downgraded Allergen (NYSE: AGN) from Overweight to Equalweight.
For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.
Shares of Allergen closed at $113.55 yesterday, with a 52 week range of $81.28-$116.45.... More
Allergan (AGN) Strong With or Without DARPin - RBC
May 1, 2013 12:02 PM EDTAnalysts at RBC Capital think the market overreacted to news about Allergen's (NYSE: AGN) DARPin. Today Allergan's CEO said data on DARPin does not support Phase 3 trials, which will delay approval by 1-2 years. This sent shares lower by well over 10 percent, but RBC... More
Allergan, Inc. (AGN) trading paused for volatility
May 1, 2013 11:06 AM EDTAllergan, Inc. (NYSE: AGN) trading paused for volatility.... More
